About LUYE PHARMA Company

Luye Pharmaceutical Group Co., Ltd. (the “Company”, together with its subsidiaries, collectively, the “Group”) is committed to the development, production, promotion and sale of innovative drugs in the four largest and rapidly growing treatment fields (i.e. oncology, central nervous system (“central nervous system”), cardiovascular system, and digestion and metabolism) in the People's Republic of China (“China”), the United States of America (“the United States”), Europe and other countries or regions. The Group's product portfolio includes more than 30 products, covering more than 80 countries and regions around the world, including large-scale pharmaceutical markets China, the United States, Europe and Japan, as well as rapidly developing emerging markets. In China, the Group has established a huge national sales and distribution network. As of the year ended December 31, 2023 (the “reporting period”), its products were sold to 31 provinces, autonomous regions and municipalities across the country. The Group carries out sales, marketing and distribution work through about 1,000 sales and marketing personnel and a network of about 1,700 dealers, which together enabled the Group to sell its products to more than 21,660 hospitals. The Group's business covers 80 countries or regions, including the United States, the European Union, Japan, the Association of Southeast Asian Nations, Latin America, the Gulf Cooperation Council region and other emerging countries or regions. The Group also has strong sales partner relationships, with more than 50 partners worldwide. The Group's research and development (“R&D”) activities comprise four platforms in the field of chemical pharmaceuticals, namely long-acting and sustained-release technology, liposome and targeted drug delivery, transdermal drug delivery systems, and novel compounds. With four cutting-edge platforms of its subsidiary Shandong Boan Biotechnology Co., Ltd. (“Boan Biology”) (“Boan Biology”), the Group has expanded its R&D capabilities to the biological field, namely whole-human antibody-transgenic mice and bacteriophage display technology, bispecific T-cell Engager technology, antibody drug coupling (“ADC”) technology, and cell therapy platforms. By strategically allocating resources, the Group balances clinical development risks between patented formulations of proven compounds and novel molecular entities, as well as biosimilars and innovative biopharmaceuticals. The Company believes that the Group's R&D capabilities will become the Group's long-term competitiveness and the driving force for future growth and development. As of December 31, 2023, the Group's R&D team comprised 931 employees, including 86 doctorates and 467 master's degrees in medicine, pharmaceuticals and other related fields. On December 31, 2023, the Group obtained a total of 271 patents and 61 patents in the application stage in China, obtained a total of 508 patents overseas, and 123 patents are in the application stage. The Group will continue to invest in products in the four strategic treatment fields of oncology, central nervous system, cardiovascular and metabolism. As of December 31, 2023, the Group had 35 products under development in China at various stages of development. The drugs under development include 17 tumor products, 12 central nervous system products, and 6 other products. The Group also has 12 products under development in the US, Europe and Japan at various stages of development.